U.S. Subcutaneous Immunoglobulin Market Size Worth USD 9.46 Billion by 2034 | CAGR: 9.4%

The U.S. Subcutaneous Immunoglobulin Market size is expected to reach USD 9.46 billion by 2034, according to a new study by Polaris Market Research. The report “U.S. Subcutaneous Immunoglobulin Market Share, Size, Trends, Industry Analysis Report By Product (IgG, IgA, IgM), By Application, By End Use; Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Subcutaneous immunoglobulin (SCIG) is a therapeutic antibody preparation administered under the skin to strengthen immune defense in patients affected by compromised immunity. The U.S. subcutaneous immunoglobulin (SCIG) market is witnessing growth due to the increasing emphasis on interactive patient care, where SCIG stands out by enabling greater independence through self-administration and flexibility outside traditional clinical settings. This patient-centric focus improved treatment compliance and reduced the burden of frequent hospital visits, aligning with the broader healthcare focus on convenience, efficiency, and improved patient experience. As a result, the rising preference for personalized and home-based therapies continues to reinforce the demand for SCIG across the country.

Do you have any questions? Would you like to request a sample or make an inquiry before purchasing this report? Simply click the link below: polarismarketresearch.com/industry-analysis/us-subcutaneous-immunoglobulin-market

The U.S. subcutaneous immunoglobulin market is driven by the increasing use of SCIG in managing chronic conditions beyond primary immunodeficiencies, particularly autoimmune and neurological disorders. Its steady absorption profile, lower risk of systemic reactions, and ability to maintain stable immunoglobulin levels make it a preferred long-term therapy option for patients with complex treatment needs. The broadening of therapeutic applications highlights SCIG’s clinical versatility and growing role in improving patient outcomes across diverse healthcare settings. This expanding scope of use is a defining factor in the continued adoption and advancement of SCIG therapies in the U.S.

Top of FormU.S. Subcutaneous Immunoglobulin Market Report Highlights

• In terms of product, the IgG segment dominated the market in 2024 due to its critical role in providing effective immune protection for a wide range of immunodeficiency disorders.
• Based on application, the secondary immunodeficiency segment is expected to witness significant growth driven by the rising prevalence of chronic illnesses and the rising adoption of immunosuppressive treatments and chemotherapy.
• Based on end use, the hospitals segment held the largest share in 2024 as the primary center for initial treatment, complex case management, and patient monitoring.
• A few key market players include ADMA Biologics, Inc.; Baxter International Inc.; Biotest AG; CSL Behring; Grifols S.A.; Johnson & Johnson (Omrix Biopharmaceuticals Inc.); Kedrion S.p.A; Octapharma AG; Pfizer Inc.; Shanghai RAAS Blood Products Co. Ltd.; and Takeda Pharmaceutical Company Limited.

Polaris Market Research has segmented the market report on the basis of product type, application, and end use:

By Product Type Outlook (Revenue, USD Billion, 2020–2034)

• IgG
• IgA
• IgM

By Application Outlook (Revenue, USD Billion, 2020–2034)

• Primary Immunodeficiency Disease
• Secondary Immunodeficiency Disease

By End Use (Revenue, USD Billion, 2020–2034)

• Hospitals
• Homecare
• Clinics
• Others